Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: Cbdpotential
Search This Board: 
Last Post: 10/20/2017 11:09:04 PM - Followers: 152 - Board type: Free - Posts Today: 0

The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.

In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.

IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.

The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.



Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA News: Statement of Changes in Beneficial Ownership (4) 10/17/2017 05:12:36 PM
IDRA News: Current Report Filing (8-k) 10/17/2017 08:54:43 AM
IDRA News: Amended Statement of Changes in Beneficial Ownership (4/a) 10/05/2017 04:19:48 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 10/04/2017 07:24:12 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 10/04/2017 04:32:22 PM
#3027   Not sure what happened. This is the correct chart. Citrati 10/20/17 11:09:04 PM
#3026   Current price action. Citrati 10/20/17 10:03:57 AM
#3025   Quite the reversal today from $2.25 back up Stockdoggy 10/17/17 02:47:47 PM
#3024   Understood. Citrati 10/17/17 11:50:04 AM
#3023   I don't use charts or look for gaps monkeyfrog 10/17/17 11:44:48 AM
#3022   Curious what chart the 2.19 open gap is Citrati 10/17/17 10:53:38 AM
#3021   I had forgot bout that gap(somehow) and noticed Farmmarket1 10/17/17 09:24:40 AM
#3020   If you're "Gap trader" then $2.19 or so monkeyfrog 10/17/17 08:57:16 AM
#3019   What worries me is how it did give Farmmarket1 10/16/17 09:31:25 PM
#3018   I thought it might step down over a Citrati 10/16/17 09:27:47 PM
#3017   I agree and wish I had played this Farmmarket1 10/16/17 03:12:44 PM
#3016   Valid comments. That is why I trade around Citrati 10/16/17 03:00:48 PM
#3015   Damn tho this seems like every other drop Farmmarket1 10/16/17 02:20:48 PM
#3014   They seem to be running stops. Has hit Citrati 10/16/17 01:49:31 PM
#3013   Did anyone see the 2.50 flash simultaneously on Farmmarket1 10/16/17 01:41:52 PM
#3012   IDRA testing the 8ema today. Could test the Citrati 10/16/17 12:52:16 PM
#3011   Hope no one got shaken out with that Citrati 10/13/17 12:16:57 PM
#3010   Go $idra! Looking better and better :-) Cbdpotential 10/11/17 12:13:34 PM
#3009   Hope higher than ten bucks! JUST 10-11-12 10/10/17 08:13:55 PM
#3008   * * $IDRA Video Chart 10-10-17 * * ClayTrader 10/10/17 05:02:42 PM
#3007   Yes indeed. Definite hold right now. Citrati 10/09/17 12:10:13 PM
#3006   :) Gotcha. I agree chart looks Stockdoggy 10/09/17 11:46:10 AM
#3005   colon - ) with no spaces make Citrati 10/09/17 10:50:31 AM
#3004   Sorry-My smiley faces did not go through ?? Stockdoggy 10/09/17 10:29:22 AM
#3003   ????????. There are some smiley faces for Stockdoggy 10/09/17 10:28:05 AM
#3002   There should be some smiley faces here. Citrati 10/05/17 12:19:55 PM
#3001   Wonder if price rise is a coincidence from Citrati 09/30/17 10:56:22 PM
#3000   Testing the 2.13 b/o and the 2.14 retrace Citrati 09/28/17 01:18:34 PM
#2999   Is this it, or does this retrace tag Citrati 09/20/17 11:51:55 PM
#2998   Another high. :-D Citrati 09/19/17 12:06:28 PM
#2997   And again today. :-D Citrati 09/18/17 09:42:38 AM
#2996 Citrati 09/15/17 02:09:05 PM
#2995   Looking good (GREEN) today! :-D $IDRA Cbdpotential 09/15/17 01:56:38 PM
#2994   Mojo has returned after testing 13ema. Citrati 09/15/17 10:24:03 AM
#2993   * * $IDRA Video Chart 09-12-17 * * ClayTrader 09/12/17 04:31:11 PM
#2992   You got your wish. I sold half Stockdoggy 09/12/17 04:01:59 PM
#2991   Gap filled rebought. Citrati 09/12/17 03:44:36 PM
#2990   * * $IDRA Video Chart 09-11-17 * * ClayTrader 09/11/17 04:52:53 PM
#2989 Citrati 09/11/17 02:06:03 PM
#2988   I should have bought so much more! $idra Never go Cbdpotential 09/11/17 10:34:53 AM
#2987   Yep, Congrats. :-D Citrati 09/11/17 09:29:52 AM
#2986   Nice! $IDRA GREEN ... Follow the science ;-) Patience And Perspective Cbdpotential 09/11/17 08:44:54 AM
#2985   Great results out this morning with IMO-2125 with Stockdoggy 09/11/17 07:07:14 AM
#2984   Where have I heard that? Rarely do I kld2 09/08/17 10:07:22 AM
#2983   Perceived strength can sometimes be nothing more than ohsaycanyousee82 09/08/17 09:09:54 AM
#2982   Everyone just hoping and praying for an adjusted ohsaycanyousee82 09/08/17 09:05:57 AM
#2981   I agree Looking good here imo $idra Cbdpotential 09/08/17 08:40:52 AM
#2980   Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment Cbdpotential 09/08/17 08:39:59 AM
#2979   looks like Milano is setting things up nicely kld2 09/08/17 07:59:21 AM
#2978   So far so GREEN :-D Cbdpotential 09/07/17 12:51:11 PM